Exelixis Inc
EXELStock
$55.68+26.08%52W
Market Cap$14.01B
P/E17.90x
Div yield—
Beta0.41
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)10.80%
Price vs S&P 500 (4W)6.02%
VGM Score62.51
Market Capitalization$14.01B
P/E Ratio (Annual)17.90x
Earnings Surprise History
Q1 260.79est. 0.72
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.74
3.77
3.77
3.68
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EXELExelixis Inc | C | B | B | $55.68 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $341.79 |
About
Exelixis Inc is a biopharmaceutical company that discovers and commercializes oncology treatments. Its portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Cometriq for metastatic medullary thyroid cancer, and Cotellic (in partnership with Roche) for melanoma.